AntriaBio, Inc. – "Expanding the Treatment Options"

Publishing & Media

Share Tweet

AntriaBio, Inc. – "Expanding the Treatment Options"

New York, NY / August 4, 2014 / AntriaBio, Inc. (OTCQB: ANTB) today published a new blog post on The Chairman’s Blog, written by the Company’s VP of Clinical Development, Dr. Brian Roberts. is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In his guest blog post, Dr. Roberts shares his perspective on the clinical promise of the Company’s lead diabetes product candidate, AB101. He writes, "If AB101 is successful in clinical trials and eventually approved by the FDA and other regulatory bodies throughout the world, I believe that it would be a ground-breaking advancement in insulin replacement therapy." Read the full blog post from Dr. Brian Roberts on (

About AntriaBio, Inc.

AntriaBio is a biopharmaceutical company focused on developing novel therapeutic products for the diabetes market. AntriaBio's development strategy combines FDA approved pharmaceutical agents with its proprietary delivery technology. AntriaBio's lead product candidate is AB101, an injectable once-a-week basal insulin for Type 1 and Type 2 diabetes. For more information visit:

About is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. 

SOURCE: The Chairmans Blog